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Background: To investigate whether Chinese non–small-cell lung 
cancer (NSCLC) patients with risk of radiation pneumonitis (RP) 
(grade ≥ 3) caused by radiotherapy display reliable single-nucleotide 
polymorphism (SNP) marker(s) located on the transforming growth 
factor-beta-1 (TGFβ1) gene.
Methods: DNA was isolated from blood samples obtained from 
NSCLC patients (n = 167) treated with radiotherapy alone (n = 23) 
or chemoradiation (n = 144) with the median total radiation dose of 
56 Gy between 2007 and 2010. A comprehensive approach toward 
characterizing the TGFβ1 SNPs in Chinese patients was carried out 
in this study. Eight SNPs of the TGFβ1 gene (rs1800469, rs1800471, 
rs1982073, rs4803455, rs11466345, rs12983047, rs10417924, and 
rs10980942) were finally genotyped by the direct DNA sequencing 
method. Kaplan–Meier cumulative probability was used to assess the 
risk of RP of grade 3 or higher. Cox proportional hazard analysis was 
used to evaluate the effect of TGFβ1 genotypes on RP risk.
Results: A total of 46 patients (27.5%) developed RP of grade 3 or 
higher, based on Common Terminology Criteria for Adverse Events 
version 3.0, with a median follow-up of 29.5 months (range, 16–58). 
The rs1982073 SNP, associated with RP risk in whites, was not found 
to be associated with the risk of RP of grade 3 or higher in Chinese 
NSCLC patients. Multivariate analysis found AG/GG genotypes of 
the novel TGFβ1 SNP rs11466345 to be associated with a signifi-
cantly higher risk of RP of grade 3 or higher compared with the AA 
genotypes, after adjustment for age, smoking status, and dosimetric 
parameters (for mean lung dose, adjusted hazards ratio = 2.295, 95% 
confidence interval: 1.101–4.783, p = 0.027; for volume of normal 
lung receiving 20 GY or more radiation, adjusted hazards ratio = 
2.142, 95% confidence interval: 1.033–4.441, p = 0.041).
Conclusion: The AG/GG genotypes of novel TGFβ1 rs11466345 
were associated with a higher risk of RP in Chinese NSCLC patients 
treated with radiotherapy. The rs1982073 SNP, associated with RP 
risk in whites, was not correlated with higher RP risk in the Chinese 
patients studied. Further studies are warranted to confirm these find-
ings in different ethnic populations.
Key Words: Non–small-cell lung cancer, Radiation pneumo-
nitis, Transforming growth factor-beta-1, Single-nucleotide 
polymorphisms.
(J Thorac Oncol. 2012;7: 1668–1675)
Lung cancer is one of the most common cancers worldwide. Radiotherapy plays an important role in the treatment of 
lung cancer. Unfortunately, pulmonary injury after thoracic 
irradiation (RT) is fairly common. Radiation pneumonitis 
(RP) is one of the most common dose-limiting toxicities 
in lung cancer patients receiving radiotherapy. RP usually 
occurs within 1 to 6 months after completion of radiation 
therapy,1 but it can occur as late as 14 months after radiation 
in some patients.2 Current population-based pneumonitis 
risk assessment relies on factors that are related to the 
patient characteristics, including age; sex, race, smoking3–5; 
comorbidities such as impaired vascularity, chronic obstructive 
pulmonary disease, preexisting fibrotic diseases; or treatment, 
including chemotherapy, total radiation dose, the dose per 
fraction, and radiation dosimetric factors.2,6–9 Many studies 
have confirmed that dose and volume of radiation delivery, 
measured by mean lung dose (MLD)1,6,7 and relative volume 
of lung receiving more than a threshold dose (Vdose),2,6–9 are 
associated with the risk of RP. However, only a percentage of 
patients in whom normal lung tissue is exposed to a certain 
dose and volume of irradiation develop RP,10 suggesting that 
patient genetic makeup may play a critical role in individual’s 
response to radiotherapy and RP development.
Several recent studies have investigated plasma levels of 
transforming growth factor-beta-1 (TGFβ1) as a predictor for 
RT-induced lung injury.11,12 However, these results on the value 
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of TGFβ1 changes in plasma for predicting RP risk are inconsis-
tent13–15 partly because TGFβ1 can be produced by both tumor 
and normal tissues. Other factors, including improper handling 
of blood samples or inadequate centrifugation conditions, can 
also falsely increase the calculated level of circulating TGFβ1,16 
which seriously limits this approach for risk prediction.
Recently, several studies have addressed a possible cor-
relation between single-nucleotide polymorphisms (SNPs) in 
the TGFβ1 gene and RT-induced pneumonitis in cohorts of 
non–small-cell lung cancer (NSCLC) patients. However, these 
studies found different results in different populations.17,18 
Thus, it must be concluded that we are still far from a complete 
understanding of the genetic basis of variability in normal tis-
sue reactions when lung cancer patients undergo radiotherapy. 
The goal of this study was a comprehensive investigation of 
TGFβ1 gene variants to explain the wide range of radiosensi-
tivity observed in Chinese NSCLC patients treated with radio-
therapy, to better personalize radiotherapy for these patients.
PATIENTS AND METHODS
Patient Population and Treating Planning
All patients were of Han Chinese ethnicity (CHB). One 
hundred and sixty-seven patient DNA samples were identified 
from a database of 323 NSCLC patients treated with definitive 
radiation at Shanghai Chest Hospital affiliated to Shanghai 
Jiaotong University between January 2007 and July 2010. 
Patients with a baseline PaO
2
 value less than 80 mmHg were 
excluded from this database. Patients were staged accord-
ing to the new staging system initiated by the International 
Association for the Study of Lung Cancer in 2009.19
A treatment-planning computed tomography (CT) scan 
was performed, using intravenous contrast if the patient was 
not allergic to contrast agent. CT scans with slices 5-mm thick 
were obtained from the mandible to the lower edge of the liver. 
Lung dose–volume histograms were computed from the three-
dimensional dose distributions. Dosimetric data, including 
MLD, volume of normal lung receiving 5 Gy or more radia-
tion (V5), and volume of normal lung receiving 20 Gy or more 
radiation (V20), were available for all 167 patients. The median 
total radiation dose was 56 Gy once daily, receiving 1.8 to 2.0 
Gy per fraction to 54 to 60 Gy in 30 fractions over 6 weeks 
using a 6-MV photon linear accelerator; 15 patients (15 of 167, 
9.0%) were treated with stereotactic body radiation therapy 
using 6 to 7 Gy/fraction per day to 60 to 70 Gy/10 fractions.
Tagging SNP Selection and Genotyping
The TGFβ1 gene, located on chromosome 19, was sur-
veyed for variation from 20 kb upstream to 10 kb downstream 
of the coding region. HapMap SNP phase II data were used to 
determine the frequency of SNPs among Han Chinese, and SNP 
selection was done using the Haploview program with a minor 
allele frequency (MAF) of more than 0.05 in a Chinese popula-
tion. In the end, five SNPs (rs4803455, rs11466345, rs12983047, 
rs10417924, and rs12980942) with MAF more than 5% and 
three SNPs (rs1800469, rs1982073, and rs1800471) reported 
in the related literature17,18 were selected. A total of eight 
SNPs across the TGFβ1 gene were considered, including one 
(rs1800469) in the 5´ flanking region (promoter untranslated 
region), two (rs1982073 and rs1800471) in the exon regions, 
two (rs4803455 and rs11466345) in the intronic regions, and 
three (rs12983047, rs10417924, and rs12980942) in the 3´ 
flanking region, according to the University of California Santa 
Cruz database (http://genome.ucsc.edu/) (Table 1).
Blood samples were collected from all study par-
ticipants. DNA was purified from blood leukocytes using 
QIAamp 96 DNA Blood Kits (Qiagen, Shanghai, China). The 
eight TGFβ1 polymorphisms were genotyped by the direct 
DNA sequencing method. The sequences of polymerase chain 
reaction primers and annealing temperature are reported in 
Table 1. Genotyping was performed by laboratory personnel 
blinded to sample status, and a random 25% of the samples 
were genotyped with 100% agreement for all. Two authors 
independently reviewed the genotyping results, data entry, and 
statistical analyses.
Follow-Up
Patients were evaluated by radiation oncologists weekly 
during radiation, 3 to 4 weeks after completion of treatment, 
and every 2 months during the first 2 years. A chest CT scan 
was performed at each follow-up evaluation after comple-
tion of radiotherapy. If patients had symptoms such as fever, 
cough, or shortness of breath, they were required to have an 
immediate examination or intervention, including oral or 
intravenous steroids, oxygen, and antibiotics. A diagnosis of 
RP was made with consensus by at least two of three radia-
tion oncologists based on clinical symptoms, with or without 
radiographic infiltrate changes.
Endpoints and Statistical Analysis
Endpoints (development of grade ≥ 2 or grade ≥ 3 RP) 
were assessed and graded according to Common Terminology 
Criteria for Adverse Events version 3.0 (Table 2).20 The times 
to endpoints were calculated from radiotherapy start; patients 
not reaching the endpoint were censored at the last follow-up. 
The last follow-up date was November 1, 2011. The median 
follow-up time for all patients was 29.5 months (range, 16–58).
Patients were grouped according to their genotypes. 
Allelic differentiation estimation was undertaken using the 
SHEsis software (http://www.nhgg.org/analysis).21 Statistical 
analysis was performed using SPSS 15.0 statistical software 
(SPSS Inc., Chicago, IL). Multivariate Cox proportional 
hazards analysis was performed to calculate the hazard ratio 
(HR) and confidence interval (CI) to evaluate the influence 
of genotypes on RP risk adjusting for other covariates (p < 
0.10 in the univariate proportional hazard analyses). Kaplan–
Meier analysis was performed to estimate the cumulative 
RP probability. A p value of 0.05 or less was considered 
statistically significant.
RESULTS
Patient Characteristics and Risk 
of Radiation Pneumonitis
The patient, tumor, and treatment characteristics are 
shown in Table 3. There were 125 men and 42 women, with a 
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median age of 58 years (range, 33–82). Among them, 74.3% 
(124 of 167) had stage III disease, 32.9% (55 of 167) were 
never smokers. A total of 23 patients (13.8%) received radiation 
alone, 144 patients (86.2%) received combined platinum-based 
chemoradiation, including 102 patients (61.1%) receiving 
sequential chemoradiation and 42 (25.1%) with concurrent 
chemoradiation. Of all patients, 91.0% (152 of 167) received 
median radiation dose of 56 Gy (range, 54–60) with once a day 
(1.8–2.0 Gy/fraction), and 9.0% (15 of 167) were treated with 
stereotactic body radiation therapy using 6 to 7 Gy/fraction per 
day to 60 to 70 Gy/10 fractions. The median values for MLD, 
V20, and V5 were 9.3 Gy, 17%, and 30%, respectively. Thus for 
this study 10 Gy, 17%, and 30% were used as cutoff points for 
MLD, V20, and V5, respectively, to define patient subgroups 
for further analysis. Of all 167 patients, 46 (27.5%) developed 
RP of grade 3 or higher; 53 (31.7%) developed grade 2 RP; and 
68 (40.7%) grade 1 or lower. RP of grade3 or higher occurred 
at a median time of 2.54 ± 1.27 months (range, 0.63–4.87) after 
commencement of radiation treatment.
Table 4 shows the associations between RP of grade 
3 or higher with patient-, tumor-, and therapy-related char-
acteristics, based on univariate analysis. The result showed 
that smoking status was marginally related with RP risk 
(p = 0.061). Radiation dosimetric factors (MLD and V20) were 
strongly associated with RP risk. Patients with MLD more than 
10 Gy had a higher RP risk compared with those with MLD of 
10 Gy or lower (HR = 2.411, 95%CI 1.206– 4.820, p = 0.013), 
the same risk differences were found when using the V20 mea-
sure (HR = 2.189, 95%CI 1.089–4.399,  p = 0.028).
Radiation Pneumonitis and TGFβ1 
SNPs and Genotypes
Table 5 shows genotype distributions and lists uni-
variate proportional hazard analyses of grade 3 or higher 
RP in patients with different TGFβ1 genotypes. One SNP, 
rs11466345, showed significant allelic differentiations with 
RP of grade 3 risk (HR = 2.088, 95%CI 1.258–3.465, p = 
0.004, Table 5). Univariate proportional hazard analyses for 
all eight SNPs showed that AG/GG rs11466345 genotypes 
were associated with an increased risk of RP of grade 3 or 
higher (HR = 2.264, 95%CI 1.126–4.552, p = 0.022, Table 5). 
For rs11466345, RP of grade 3 or higher developed in 19.8% 
(17 of 86) of patients having AA genotype, whereas it devel-
oped in 35.8% (29 of 81) of patients having AG/GG genotypes 
after initiation of radiotherapy. However, none of the three 
TGFβ1 SNPs (rs1800469, rs1982073, or rs1800471) reported 
in Western patients17 were validated to be associated with RP 
risk (p = 0.663 for rs1800469 and p = 0.632 for rs1982073, 
Table 5) in our studied Chinese patients. In addition, the 
rs1800471 SNP genotype was GG in 99.4% of the patients 
(166 of 167), CG in 0.6% of the patients (1 of 167), and CC in 
0% of the patients (0 of 167), and thus was not polymorphic 
in our Chinese patient population.
To further control confounding effects, rs11466345 
genotypes in patients with RP of grade 3 or higher were 
calculated by multivariate analysis with adjustment for the 
other factors, including age, smoking status, and radiation 
dosimetric factors, for which p values for RP risk were 
less than 0.10 in the univariate proportional hazard anal-
yses (Table 6). Because V20 and MLD were significantly 
correlated with each other (r = 0.941; p < 0.001), we only 
used one of the two as the dosimetric factor. The associa-
tion between AG/GG rs11466345 genotypes and grade 3 or 
higher RP risk was virtually unchanged after adjusting by 
age, smoking status, and MLD in the multivariate analy-
sis (adjusted HR = 2.295, 95% CI 1.101–4.783, p = 0.027). 
A similar result was obtained when multivariate analysis 
was adjusted for the other dosimetric factor, V20 (adjusted 
HR = 2.142, 95% CI 1.033–4.441, p = 0.041), suggesting 
that rs11466345 polymorphism is an independent factor for 
RP risk.
TABLE 1.  Selected SNPs and PCR Primers of the TGFβ1 Gene in the Han Chinese Population
NCBI dbSNP PCR Primers
Tm (°C)
ID/Ref. Location 
(UCSC)
Location in 
Gene
Base 
Change
Forward Reverse
rs1800469 41860296 5´-flanking T/C CAGGGTGTTGAGTGACAGGA ACCCAGAACGGAAGGAGAGT 61
rs1982073 41858876 Exon 1 T/C TATGAGGATGTGGTGCGTGT TGGGGTGGTGTTTACGTGATG 61
rs1800471 41858921 Exon 1 G/C CTGTGGCTACTGGTGCTGAC CTCCGGTTCTGCACTCTCC 61
rs4803455 41851509 Intron 2 C/A CTGCAACCTCTGTGTCTTGG CTGAGCATACGGTTCTGCAA 61
rs11466345 41843461 Intron 5 A/G CCATGTCCAAGGGTCAGTCT ACAGCTGGCCTGATTTTTGT 61
rs12983047 41834499 3´-flanking G/A TATGAGGATGTGGTGCGTGT TGGGTGGTGTTTACGTGATG 61
rs10417924 41833167 3´-flanking T/C GGAGATTGGTGGGTGAGAGA CCACAAACACACGGAGCTAA 61
rs12980942 41832231 3´-flanking G/A CATGCTTCCTGTGGTTCTCA TGCTCACAAACACACATCCA 61
SNP, single-nucleotide polymorphism; PCR, polymerase chain reaction; NCBI, National Center for Biotechnology Information; ID, identification; TGFβ1, transforming growth 
factor-beta-1.
TABLE 2.  Common Toxicity Criteria for Adverse Events 
 version 3.0
Adverse Event Grade Description
Pneumonitis 1 Asymptomatic, radiographic findings only
2 Symptomatic, not interfering with ADL
3 Symptomatic, interfering with ADL; O
2
 indicated
4 Life-threatening; ventilatory support indicated
5 Death
ADL, activities of daily life.
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Association of Genotype and 
Dosimetric Factor with RP Risk
Figure 1A plots the Kaplan–Meier incidence of RP of 
grade 3 or higher as a function of time for the AG/GG gen-
otype in rs11466345 (p = 0.034). To identify higher-order 
interactions in the risk of developing RP, we carried out a 
classification analysis according to genotype and dosimet-
ric factor (MLD or V20). Patients with AA genotypes in 
rs11466345, who received MLD of 10 Gy or lesser had the 
lowest RP incidence in the entire studied group (p = 0.028; 
Fig. 1B). The same results were obtained when using the V20 
factor. Patients with AG/GG genotypes in rs11466345, who 
received V20 more than 17% of their normal lung volume had 
the highest RP risk of the entire studied group (p = 0.036, 
Fig. 1C). The association of RP risk with AG/GG rs11466345 
genotypes was consistent across different subgroups, both in 
the patients who received MLD more than 10 Gy or V20 more 
than 17%, and in the patients receiving 10 Gy MLD or lesser 
or 17% or lesser V20, suggesting that the genetic predisposi-
tion was independent of dosimetric factors.
DISCUSSION
Recently, several studies have analyzed correlations 
between candidate polymorphisms in the TGFβ1 gene and 
RT-induced pneumonitis in cohorts of NSCLC patients.17,18 
TABLE 3.  Patient Characteristics (N = 167)
Characteristic No. of Patients %
Sex
 Male 125 74.9
 Female 42 25.1
Age, yrs
 Mean ± SD 58 ± 9
 ≤58 yrs 89 53.3
 >58 yrs 78 46.7
Stage
 I 9 5.4
 II 13 7.8
 III 124 74.3
 IV 21 12.6
Histology
 Squamous cell 65 38.9
 Adenocarcinoma 78 46.7
 NSCLC, NOS 24 14.4
Smoking status
 Smokers 112 67.1
 Nonsmokers 55 32.9
Treatment
 Radiation alone 23 13.8
 Chemoradiation 144 86.2
 Sequential 
chemoradiation
102 61.1
 Concurrent 
chemoradiation
42 25.1
Radiation dose, Gy
 Mean ± SD 56.0 ± 7.5
 ≤56 Gy 67 40.1
 >56 Gy 100 59.9
Mean lung dose, Gy
 Mean ± SD 9.3 ± 3.9
 ≤10 Gy 102 61.1
 >10 Gy 65 38.9
V5, %
 Mean ± SD 30.1 ± 11.7
 ≤30% 89 53.3
 >30% 78 46.7
V20, %
 Mean ± SD 17.0 ± 8.3
 ≤17% 85 50.9
 >17% 82 49.1
NSCLC NOS, non–small-cell lung cancer, not otherwise specified; V5, volume of 
normal lung receiving 5 GY or more radiation; V20, volume of normal lung receiving 
20 GY or more radiation.
TABLE 4.  Univariate Analysis of Associations between Grade 
≥ 3 Radiation Pneumonitis and Patient-, Tumor-, Therapy-
Related Characteristics (N = 167)
Grade≥3 Radiation Pneumonitis
Characteristic HR 95% CI p
Sex
 Male 1.000
 Female 0.773 0.344–1.734 0.532
Age, yrs
 ≤58 yrs 1.000
 >58 yrs 1.950 0.979–3.885 0.057
Stage
 I, II 1.000
 III, IV 2.670 0.751–9.495 0.129
Histology
 Adenocarcinoma 1.000
 Nonadenocarcinoma 1.197 0.604–2.370 0.606
Smoking status
 Smokers 1.000
 Nonsmokers 0.469 0.213–1.035 0.061
Treatment
 Radiation alone 1.000
 Chemoradiation 2.838 0.801–10.055 0.106
Mean lung dose, Gy
 ≤10 Gy 1.000
 >10 Gy 2.411 1.206–4.820 0.013
V5, %
 ≤30% 1.000
 >30% 1.527 0.772–3.022 0.224
V20, %
 ≤17% 1.000
 >17% 2.189 1.089–4.399 0.028
HR, hazard ratio; CI, confidence interval; V5, volume of normal lung receiving 5 
GY or more radiation; V20, volume of normal lung receiving 20 GY or more radiation.
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However, results have differed worldwide.17,18 To study the 
genetic variants of TGFβ1 associated with RP risk in different 
populations, we carried out a comprehensive study of genetic 
variants in the entire gene. In this study, AG/GG genotypes 
of the novel TGFβ1 SNP rs11466345 were associated with 
a higher risk of RP in Chinese NSCLC patients treated with 
radiotherapy. None of the three TGFβ1 SNPs (rs1800469, 
rs1982073, rs1800471) reported in Western countries,17 espe-
cially rs1982073, were found to be associated with RP risk in 
our cohort of Chinese patients.
TGFβ1 is one of the most extensively studied 
cytokines in the development of tissue fibrosis in response to 
irradiation,22 and TGFβ1 signaling is an important modulator 
of the inflammatory response. Animal and human studies have 
demonstrated that TGFβ1 is a major regulator of radiation-
induced lung injury23 as a master switch for development 
and persistence of fibrosis.24 Administration of anti-TGFβ 
antibodies can decrease the inflammatory response and reduce 
TGFβ activation several weeks after RT, further suggesting 
that targeting the TGFβ pathway may be a useful strategy to 
prevent RT-induced lung injury.25 However, a major concern 
is that plasma values of TGFβ1, used for predicting RP risk, 
are inconsistent in the irradiated lung.13–15 Excessive platelet 
degranulation by freezing plasma and long centrifugation 
is a major problem for the detection of plasma TGFβ1,26 
which seriously limits this approach for risk prediction.16 
Radiogenomics with genotyping analysis of SNPs in TGFβ1 
and TGFβ1 pathway genes may allow the identification of 
genotypes prone to RP.27,28
Taking into account different genetic backgrounds 
in different populations, a comprehensive approach toward 
characterizing TGFβ1 SNPs in Chinese patients was carried 
out in our study. We did not use a candidate polymorphism 
approach, which would have allowed us to focus on poten-
tially functional SNPs reported in the literature, but rather 
comprehensively covered all SNPs in the entire gene. This 
TABLE 5.  Univariate Analysis of Associations between TGFβ1 Alleles and Genotypes and Grade ≥ 3 Radiation Pneumonitis
SNPs Allele
No. of Events/
Total HR (95% CI) p Genotypes
No. of Events/
Total HR (95% CI) p
rs1800469 T 53/186 Reference CC 8/29 Reference
C 39/148 1.114 (0.686–1.809) 0.663 CT 23/90 0.901 (0.351–2.312) 0.829
TT 15/48 1.193 (0.431–3.301) 0.734
CT+TT 38/138 0.998 (0.407–2.443) 0.996
rs1982073 T 38/145 Reference TT 8/28 Reference
C 54/189 0.888 (0.546–1.444) 0.632 CT 22/89 0.821 (0.317–2.124) 0.684
CC 16/50 1.176 (0.427–3.238) 0.753
CT+CC 38/139 0.941 (0.382–2.315) 0.894
rs1800471 G 92/333 NC NC GG 46/166 NC NC
C 0/1 CG 0/1
CC 0/0
CG+CC 0/1
rs4803455 C 65/219 Reference AA 3/13 Reference
A 27/115 1.376 (0.818–2.313) 0.228 AC 21/89 1.029 (0.259–4.091) 0.967
CC 22/65 1.705 (0.425–6.838) 0.451
AC+CC 43/154 1.291 (0.339–4.919) 0.708
rs11466345 A 54/235 Reference AA 17/86 Reference
G 38/99 2.088 (1.258–3.465) 0.004 AG 20/63 1.888 (0.891–3.998) 0.097
GG 9/18 4.059 (1.398–11.780) 0.010
AG+GG 29/81 2.264 (1.126–4.552) 0.022
rs12983047 G 35/115 Reference AA 16/66 Reference
A 57/219 1.243 (0.755–2.048) 0.392 AG 25/87 1.260 (0.607–2.614) 0.535
GG 5/14 1.736 (0.508–5.938) 0.379
AG+GG 30/101 1.320 (0.651–2.676) 0.441
rs10417924 T 18/55 Reference CC 29/117 Reference
C 74/279 1.348 (0.723–2.512) 0.347 CT 16/45 1.674 (0.798–3.512) 0.173
TT 1/5 0.759 (0.081–7.063) 0.808
CT+TT 17/50 1.563 (0.761–3.212) 0.224
rs10980942 G 66/248 Reference AA 4/11 Reference
A 26/86 0.837 (0.488–1.435) 0.517 AG 18/64 0.685 (0.179–2.625) 0.581
GG 24/92 0.618 (0.166–2.297) 0.472
AG+GG 42/156 0.645 (0.180–2.315) 0.501
SNP, single-nucleotide polymorphism; HR, hazard ratio; CI, confidence interval; NC, not calculated.
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approach would warrant additional investigation of the other 
tagging SNPs that may have been missed in the previous stud-
ies only using the candidate polymorphism method. Because 
a patient’s genome can contain genetic variants in both proin-
flammatory and anti-inflammatory pathways, this comprehen-
sive approach is much more powerful in detecting the effect 
of these SNPs on a patient’s risk of developing pneumonitis.
In our study, TGFβ1 rs11466345 polymorphisms were 
associated with RP risk in CHB NSCLC patients treated with 
radiotherapy. Analyzing AG/GG genotypes in rs11466345 
with MLD/V20 dosimetric measures seemed to help facilitate 
stratification of patients into low-, intermediate-, and high-
risk groups and further improve predictive power. Our data 
show that the incidence of RP was lowest in the group with the 
rs11466345 AA genotype and MLD of 10 Gy or less or V20 
of 17% or lower. These findings provide strong support for 
the novel notion that the rs11466345 polymorphism is associ-
ated with RP risk in the CHB population. Because this genetic 
information can be obtained before the radiation treatment is 
initiated, this test could be used, in addition to radiation dosi-
metric factors, as a predictive biomarker to prescribe person-
alized radiation therapy in Chinese NSCLC patients.
Results of association studies investigating RP and three 
other SNPs (rs1800469, rs1982073, rs1800471) in different 
populations,17,18 including this study, are summarized in Table 7. 
Another Chinese study showed no association between RP risk 
and three TGFβ1 SNPs (rs1982073, rs1800469, rs1800471) 
among NSCLC cases treated with radiotherapy, and the same 
result was confirmed by our study—the only study to date 
which comprehensively covered all SNPs in the TGFβ1 gene. 
Association between the rs1982073 polymorphism and RP risk 
has been commonly observed in white populations,17 whereas 
no association was found for Chinese patients,18 including 
those in our study. For the rs1800469 SNP, the MAFs for T 
allele in different populations varied, with reports of 0.288, 
0.196, and 0.474 in whites, African Americans, and CHB, 
respectively, based on HapMap data. In addition, rs1800471 is 
a common SNP (MAF = 0.070 for C allele) in whites, but was 
not polymorphic at all in our CHB patients.18 Different genetic 
backgrounds between whites and CHB may explain, at least in 
part, these discrepancies.
Smoking status was marginally related with RP risk in 
our study (p = 0.064 in the multivariate analysis of MLD, p = 
0.079 in the multivariate analysis of V20). Till now, the influ-
ence of smoking history on RP risk has been quite unclear. 
TABLE 6.  Multivariate Analysis of TGFβ1 Genotypes Associations with Grade ≥ 3 Radiation Pneumonitis
Parameter HR 95% CI p Parameter HR 95% CI p
Age, yrs Age, yrs
 ≤58 1.000   ≤58 1.000
 >58 2.008 0.965–4.180 0.062  >58 2.052 0.991–4.250 0.053
Smoking status Smoking status
 Smokers 1.000  Smokers 1.000
 Nonsmokers 0.448 0.191–1.047 0.064  Nonsmokers 0.472 0.204–1.091 0.079
MLD, Gy V20, %
 ≤1 0Gy 1.000   ≤17% 1.000
 >10 Gy 2.841 1.354–5.964 0.006  >17% 2.411 1.152–5.046 0.019
rs11466345 rs11466345
 AA 1.000  AA 1.000
 AG+GG 2.295 1.101–4.783 0.027  AG+GG 2.142 1.033–4.441 0.041
Because MLD and V20 were significantly correlated with each other (r = 0.941; p < 0.001), either MLD or V20 was used in multivariate analyses, but not together.
Multivariate analysis was performed with adjustment for the other factors, including age, smoking status, and radiation pneumonitis dosimetric factors (MLD or V20), for which 
p values for radiation risk were < 0.10 in the univariate proportional hazard analyses.
HR, hazard ratio; CI, confidence interval; V20, volume of normal lung receiving 20 GY or more radiation; MLD, mean lung dose. 
TABLE 7.  Association of TGFβ1 SNP with RP Risk in Different 
Ethnic NSCLC Patients
SNP
Association with RP 
Risk
p in 
Univariate 
Analysis
Study 
Group Reference
Events/ 
Total
Events/ 
Total
rs1800469 CC CT or TT
25/100 11/63 0.231 Whitea 17
8/44 20/126 0.810 Northern 
Chineseb
18
8/29 38/138 0.996 Southern 
Chinesea
Current 
study
rs1800471 GG CG or CC
33/144 3/20 0.476 Whitea 17
179/179 0/0 NC Northern 
Chineseb
18
46/166 0/1 NC Southern 
Chinesea
Current 
study
rs1982073 TT CT or CC
17/52 18/111 0.017 Whitea 17
8/54 20/125 0.840 Northern 
Chineseb
18
8/28 38/139 0.894 Southern 
Chinesea
Current 
study
aAssociation with radiation pneumonitis of grade 3 or higher.
bAssociation with radiation pneumonitis of grade 2 or higher.
SNP, single-nucleotide polymorphism; RP, radiation pneumonitis; NSCLC, non–
small-cell lung cancer.
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Possible explanations of a decreased inflammatory reaction 
among smokers include smoking-associated hypoxia; a com-
promised capacity to repair DNA damage in nonsmoking 
patients, predisposing them to increased lung toxicity after 
radiotherapy.3 Although data from several other studies sug-
gest that nonsmoker is associated with important benefits 
such as better lung function with regard to diffusing capac-
ity of the lung for carbon monoxide and forced expiratory 
volume in 1 second.4,5 So the smoking role in RP risk is still 
unclear and controversial. The results should in no way be 
taken to encourage patient smoking; rather, further investiga-
tions on underlying causes for the smoking effect should be 
undertaken.
There are still several limitations to our study. First, 
the SNP (rs11466345) associated with risk in our study is 
intronic, and there is debate regarding the true function of this 
polymorphism. A recent study29 demonstrated that the haplo-
type block in which rs11466345 lies also covers the last two 
exons and the 3´ untranslated region of the TGFβ1 gene. Thus, 
it is possible that this SNP is in linkage disequilibrium with a 
causal SNP, which may either result in a change in amino acid 
or affect a possible splice variant or the stability of the mRNA, 
but this is so far unknown. A recent study29 has reported that 
SNP rs11466345 (GG) of TGFβ1 was correlated with a sta-
tistically significant lower risk of colorectal adenocarcinoma, 
and a haplotype containing SNP rs11466345 was associated 
with genetic susceptibility to colorectal neoplasia. Further 
studies are needed to elucidate the mechanism by which 
rs11466345 in TGFβ1 affects RP risk in NSCLC patients 
treated with radiotherapy.
FIGURE 1.  The effects of single-nucleotide polymorphism at TGFβ 1 rs11466345 and dosimetric parameters on the cumu-
lative incidence of RP of grade 3 or higher. A, Patients with the AG/GG genotypes of TGFβ1 rs11466345 had a statistically 
significant higher incidence of grade 3 or higher RP compared with AA genotype patients (p = 0.034). B, Patients with the 
AG/GG genotypes of TGFβ1 rs11466345 and MLD more than 10 Gy had a statistically significant higher incidence of grade 3 
or higher RP compared with AA genotype patients (p = 0.028). C, Patients with the AG/GG genotypes of TGFβ1 rs11466345 
and V20 higher than 17% had a statistically significant higher incidence of grade 3 or higher RP compared with AA genotype 
patients (p = 0.036). RP, radiation pneumonitis; TGFβ1, transforming growth factor-beta-1; MLD, mean lung dose; V20, vol-
ume of normal lung receiving 20 GY or more radiation.
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Second, no baseline pulmonary function analysis was 
performed in our study. However, patients with a PaO
2
 value 
of less than 80 mmHg, which was independently associated 
with severe RP more often than a higher PaO
2
 value (19% ver-
sus 5%, p = 0.034),30 were excluded from our study. In addi-
tion, in several studies, pulmonary function before irradiation 
was further demonstrated to have no association with the risk 
of RP, in populations of white,17 Chinese,18 and Japanese lung 
cancer patients.30 Further follow-up and quantitative analysis 
of lung function might be needed to ascertain longer tolerance 
of radiation therapy.
In conclusion, our results suggest that the AG/GG geno-
types of novel TGFβ1 SNP rs11466345 were associated with a 
higher risk of RP in CHB NSCLC patients treated with radio-
therapy. Furthermore, rs1982073, associated with RP risk in 
white patients, was not associated with RP risk in our Chinese 
patients. This lack of association, which differed markedly 
from studies of white patients, may suggest the presence of 
different mechanisms in the pathogenesis of RP among dif-
ferent ethnic groups. Further large-scale studies are required 
to confirm these findings before polymorphisms can be used 
as predictive markers to individualize radiation therapy on a 
genetic basis.
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